{"name":"Alseres Pharmaceuticals, Inc","slug":"alseres-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMicEFVX3lxTE50RERjT2lTWGJIcGsxUjRTSkU5THRhaEtKV0NkSkZqNzJOMWJxQV9kVFdSa0d6ajItb1dqc3pVNWRxMFJXTnR1Ti0zR1E3dU1JNVlZY1hOX19aWEZpY0RtRjhGcmVXY3k2TnlwbXJzTWU?oc=5","date":"2025-10-07","type":"pipeline","source":"Market.us","summary":"Neurological Biomarkers Market Size, Share | CAGR of 11.9% - Market.us","headline":"Neurological Biomarkers Market Size, Share | CAGR of 11.9%","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxQWVpqb2Q1WjVBX09ONXlEOHVzTzlkSHlKdGEtSzcxc2hGYlM1T1E5SmdmaHA3TG8wQ1RWRF8tbmFiUGlJcm5rYVh6cUlQZWdDeGtFeGhhUHNOdkRvbXFIUGxLU2t4OEFFdDhyQ3lBa2hvaHJGZkNxV29XUkVZcmtTRA?oc=5","date":"2023-10-31","type":"pipeline","source":"Straits Research","summary":"Central Nervous System Biomarkers Market Size, Top Share, Forecast to 2033 - Straits Research","headline":"Central Nervous System Biomarkers Market Size, Top Share, Forecast to 2033","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxONkpqRmdrNnoyVHd0Rmp0QzJiME80RDFEQml4UzRWTzdLOXluSDJhNUU1Z3liMTRDck1kZ1N6Z1JTWkJPbzI0MndzcE1qeDhzaVRBdEN3eHR6djFKcWFoSExDd1BtUWc3RnlzNF9pTVRGYVFaeWY1ekJmSTZuU0hUZWJZNGZVVWFNR1ZyNEFDOVhMT0FWaUl2NkRuUWZMakE0T3J0REZSVThTNmd1aS03ZmE4WmVlUXcwb1Y4OGJpR2M?oc=5","date":"2021-09-17","type":"pipeline","source":"BioWorld News","summary":"Entrepreneur Paul Hopper launches Radiopharm Theranostics following AU$20M series A - BioWorld News","headline":"Entrepreneur Paul Hopper launches Radiopharm Theranostics following AU$20M series A","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQb3JyQWIxX1FvTEZDXzNEbU1yVWJKaVl2ZXpRRkxVWlpBMWhPSFcyUkdVYWFuaXB3R0NGT3E2OGx0Uk5nQ245WWxtcGZ2dndLZG9VRm5tUmpmR25CTHlGbkNvRm41aGNTN2dIM2tvcGh1OHdlZkJ3bDBJZFFzR1J5Zk1YZ1ZHMzBqREN1ZldNOE5wV1lqNWxR?oc=5","date":"2018-10-25","type":"trial","source":"Fierce Biotech","summary":"Vertex halts phase 2b spinal injury trial for futility - Fierce Biotech","headline":"Vertex halts phase 2b spinal injury trial for futility","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMi2AJBVV95cUxNbTY0VV80N0laamN5Z3hZc2JtZGRXa0NESy1jc3JyNkljclNWbTIwaWNjVGhFbk5PcWhxclNXRmtuRkVERHBZTFExb3hjTXFDYTd6MUtfQ3V0RF9Ea04zTF9KaktBenRPQUxHU01JbGhkZ0JzcW5FUTN6STBwbUIyQXhJeWlfNVN3dE50Yjh1bTlULXhaUHhZdFIyN2kyZ3JrY19Qb3BPQ1BpV3R1S2RQSnRpSjE4eU9hMFlxUXpLSGV1anFybEhHdzRLX1FyRjRpbmhWX092b3o5UVE0dkNHSEwyeW44ZFNWeU9JRkx4MnNOYnpmX21qb3hmRk96c0RwTlBrYTZPTmQ3T0JfVExwZE5MSHFZX1MtM1F0dzRwTW9hYUxLeUxxdUVrbjlMSnpxMEQzMDJKaEhFVWVucXpfS1RwcnZvbUR1R1NCaWkyUDRLbWg3emQ0eQ?oc=5","date":"2018-06-29","type":"pipeline","source":"openPR.com","summary":"Worldwide Radiopharmaceuticals Market Size by focusing on Top - openPR.com","headline":"Worldwide Radiopharmaceuticals Market Size by focusing on Top","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNZDhkaW9fUUNRNEgyZ0RJeXRJTWFxS3ZXcVdvRWdaOVV2a0YxVmhhOHRsSk1DT0VQUVotLXU5UVE1ZXlmZU9MQ3JINzdvdXBnNTFNMmg0OHBVb0REU0FhRDZUc01EcFMxRWZ5TjFGUUpiLUNVcmJ3ay15MW9FbTF2a2NEU1kya3NiUHZrTGE5b1hXZTJsVHN1VS1fbXFLNFBsUmc?oc=5","date":"2015-12-31","type":"pipeline","source":"New Jersey Business Magazine","summary":"FluoroPharma Names Dr. Thomas Tulip, PhD Chief Executive Officer - New Jersey Business Magazine","headline":"FluoroPharma Names Dr. Thomas Tulip, PhD Chief Executive Officer","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}